Menu

Applications

Discover What We’ve Been Working On.

Scores of attempts have been made to deliver biologics orally, and most have failed. We believe Rani’s approach will transform the market, and we are on the way to proving that it is nothing short of a breakthrough. Rani has successfully:

  • Tested multiple molecules on our platform, including internal programs and partner molecules
  • Conducted preclinical tests that consistently demonstrated that the RaniPill™ capsule delivery is equivalent to a subcutaneous injection
  • Completed a successful Phase I study with Octreotide

Potential Molecules for the RaniPill™ Capsule

Octreotide

Octreotide can lower levels of excess growth hormone for the treatment of acromegaly, a disorder characterized by enlargement of face, hands and feet. It can also treat diarrhea associated with certain types of tumors. The Rani platform could eliminate injections for these patients and replace them with a daily pill.

Rani has demonstrated bioavailability equivalent to subcutaneous injections in pre-clinical studies. Octreotide was our first molecule to be tested with the RaniPill in humans. Our Phase I study with Octreotide was conducted in mid-2019.

 

Potential Molecules for the RaniPill™ Capsule

TNF-alpha (TNFα) Inhibitors

TNF-alpha (TNFα) inhibitors suppresses response to tumor necrosis factor, part of the inflammatory response. TNFα Inhibitors are used to treat a number of inflammatory disorders including rheumatoid arthritis and Crohn’s disease. A Rani product could transform this therapy replacing painful, biweekly injections with a daily pill.

Rani has demonstrated bioavailability equivalent to subcutaneous injections in pre-clinical studies.

Potential Molecules for the RaniPill™ Capsule

Parathyroid Hormone (PTH)

Commonly used for the treatment of osteoporosis and hypoparathyroidism, PTH increases the concentration of calcium in the blood by acting upon the parathyroid hormone 1 receptor and the parathyroid hormone 2 receptor.  A Rani product could transform this therapy replacing painful, daily injections with daily pills.

Rani has demonstrated bioavailability equivalent to subcutaneous injections in pre-clinical studies.

Potential Molecules for the RaniPill™ Capsule

Human Growth Hormone (HGH)

Human Growth Hormone (HGH) is a peptide hormone that stimulates growth, cell reproduction and regeneration, and is used in the treatment of growth disorders and growth deficiency. A Rani product could transform this therapy replacing painful weekly or daily injections with daily pills.

Potential Molecules for the RaniPill™ Capsule

Factor VIII

Factor VIII are used for the treatments of blood clotting disorders including Hemophilia A.  The RaniPill™ could be used for routine prophylaxis to reduce the frequency of bleeding episodes and perioperative management of bleeding. 

Potential Molecules for the RaniPill™ Capsule

GLP-1 Analog

Glucagon-like peptide-1 agonists or GLP-1 mimetics are a class of drugs used in the treatment of Type II diabetes and obesity. Available GLP-1 agonists include exenatide, liraglutide and lixisenatide. Currently, patients must administer a daily or weekly injection. The Rani platform could transform this therapy with daily pills.

Rani has demonstrated bioavailability equivalent to subcutaneous injections in pre-clinical studies.

 

Potential Molecules for the RaniPill™ Capsule

Basal Insulin

Basal insulin or “background insulin” is used in diabetes management as a way to regulate glucose levels in between meals.  The RaniPill™ could change the lives of millions of diabetes patients by radically reducing the amount and frequency of injections.

Octreotide

TNFα Inhibitors

Parathyroid Hormone (PTH)

Human Growth Hormone (HGH)

Factor VIII

GLP-1

Basal Insulin

“Millions must take injections to slow the progression of their condition.  With pills, compliance is much higher than with injections which helps slow down chronic diseases.”

Mir Imran, Founder and Executive Chairman

“I am passionate about changing healthcare and coming up with new solutions that will impact the lives of millions of patients.”

Mir Imran, Founder

“Given the market demand and potential, it’s no wonder that there have been more than a hundred attempts and billions of dollars spent by companies to try to convert painful injections into painless pills.”

Mir Imran, Founder